The Role of the Advanced Patient Derived Models in Tumors and Translational Medicine

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Tumor Microenvironment".

Deadline for manuscript submissions: closed (20 December 2023) | Viewed by 2633

Special Issue Editor


E-Mail Website
Guest Editor
1. Division of Biomedical Research, Medical University of Graz, 8036 Graz, Austria
2. BioTechMed-Graz, Mozartgasse 12/II, A-8010 Graz, Austria
Interests: malignant melanoma; extracellular vesicles

Special Issue Information

Dear Colleagues,

To develop a reliable tool for personalized cancer therapy and innovative drug development, the key features of the original tumor must be preserved in vitro over time. Recapitulation of the tissue microenvironment (TME) is challenging in vitro but necessary for the development of experimental cancer models. The translational gap between the preclinical and clinical domains could be improved with excellent outstanding in vitro cell models. Not only different cells from a patient, but also downsizing of tumor models using microfluidic platforms can be used to study the behavior and biology of cancer cells and optimally reflect the physiological environment in which they naturally occur. It is important to break new ground and move away from the old familiar cell lines that are far from the real in vivo situation The goal of this Special Issue is to present and promote advanced tumor models that can be reliably and reproducibly used in vitro and to make them available to the research community. Understanding these interactions can help to implement better therapeutic regimens for cancer treatment.

In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:

  • Presenting highly characterized tumor cell lines which mimic the in vivo situation as close as possible;
  • Establishing advanced tumor models, which can be used for the whole society;
  • Determining the role of cancer-associated fibroblast in tumors by establishing adequate models;
  • Using microfluidic platforms to minimize models.

We look forward to receiving your contributions.

Dr. Beate Rinner
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cell culture techniques
  • cancer research
  • tumor microenvironment and microfluidic
  • tumor modeling
  • patient derived models

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

21 pages, 1568 KiB  
Review
Patient-Derived Models of Cancer in the NCI PDMC Consortium: Selection, Pitfalls, and Practical Recommendations
by Amber N. Habowski, Deepthi P. Budagavi, Sandra D. Scherer, Arin B. Aurora, Giuseppina Caligiuri, William F. Flynn, Ellen M. Langer, Jonathan R. Brody, Rosalie C. Sears, Giorgia Foggetti, Anna Arnal Estape, Don X. Nguyen, Katerina A. Politi, Xiling Shen, David S. Hsu, Donna M. Peehl, John Kurhanewicz, Renuka Sriram, Milagros Suarez, Sophie Xiao, Yuchen Du, Xiao-Nan Li, Nora M. Navone, Estefania Labanca and Christopher D. Willeyadd Show full author list remove Hide full author list
Cancers 2024, 16(3), 565; https://doi.org/10.3390/cancers16030565 - 29 Jan 2024
Viewed by 2363
Abstract
For over a century, early researchers sought to study biological organisms in a laboratory setting, leading to the generation of both in vitro and in vivo model systems. Patient-derived models of cancer (PDMCs) have more recently come to the forefront of preclinical cancer [...] Read more.
For over a century, early researchers sought to study biological organisms in a laboratory setting, leading to the generation of both in vitro and in vivo model systems. Patient-derived models of cancer (PDMCs) have more recently come to the forefront of preclinical cancer models and are even finding their way into clinical practice as part of functional precision medicine programs. The PDMC Consortium, supported by the Division of Cancer Biology in the National Cancer Institute of the National Institutes of Health, seeks to understand the biological principles that govern the various PDMC behaviors, particularly in response to perturbagens, such as cancer therapeutics. Based on collective experience from the consortium groups, we provide insight regarding PDMCs established both in vitro and in vivo, with a focus on practical matters related to developing and maintaining key cancer models through a series of vignettes. Although every model has the potential to offer valuable insights, the choice of the right model should be guided by the research question. However, recognizing the inherent constraints in each model is crucial. Our objective here is to delineate the strengths and limitations of each model as established by individual vignettes. Further advances in PDMCs and the development of novel model systems will enable us to better understand human biology and improve the study of human pathology in the lab. Full article
Show Figures

Figure 1

Back to TopTop